| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A benchmark for neural network robustness in skin cancer classification
|
Maron, Roman C.
|
|
|
155 |
C |
p. 191-199
|
artikel
|
| 2 |
Association between the dietary regimen and infection-related complications in neutropenic high-risk patients with cancer
|
Jakob, Carolin E.M.
|
|
|
155 |
C |
p. 281-290
|
artikel
|
| 3 |
Breast cancer diagnosed in the post-weaning period is indicative for a poor outcome
|
Lefrère, Hanne
|
|
|
155 |
C |
p. 13-24
|
artikel
|
| 4 |
Cancer and immunotherapy: a role for microbiota composition
|
Pham, Fiona
|
|
|
155 |
C |
p. 145-154
|
artikel
|
| 5 |
Cancer survival in women diagnosed with pregnancy-associated cancer: An overview using nationwide registry data in Sweden 1970–2018
|
Johansson, Anna L.V.
|
|
|
155 |
C |
p. 106-115
|
artikel
|
| 6 |
COVID-19 mRNA vaccines and immune-related adverse events in cancer patients treated with immune checkpoint inhibitors
|
Chen, Yu-Wei
|
|
|
155 |
C |
p. 291-293
|
artikel
|
| 7 |
Development and validation of prognostic nomograms for single large and huge hepatocellular carcinoma after curative resection
|
Wang, Jun-Cheng
|
|
|
155 |
C |
p. 85-96
|
artikel
|
| 8 |
Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial
|
Caffo, Orazio
|
|
|
155 |
C |
p. 56-63
|
artikel
|
| 9 |
Erratum to “α4 contributes to bladder urothelial carcinoma cell invasion and/or metastasis via regulation of E-cadherin and is a predictor of outcome in bladder urothelial carcinoma patients” [Eur J Canc 50 (2014) 840–851]
|
Liu, Jianye
|
|
|
155 |
C |
p. 317
|
artikel
|
| 10 |
Fasciitis induced by sintilimab in a patient with recurrent hepatocellular carcinoma
|
Ning, Cong
|
|
|
155 |
C |
p. 296-298
|
artikel
|
| 11 |
Feasibility of magnetic resonance imaging-based radiomics features for preoperative prediction of extrahepatic cholangiocarcinoma stage
|
Huang, Xinqiao
|
|
|
155 |
C |
p. 227-235
|
artikel
|
| 12 |
Gastrointestinal cancer classification and prognostication from histology using deep learning: Systematic review
|
Kuntz, Sara
|
|
|
155 |
C |
p. 200-215
|
artikel
|
| 13 |
Increased risk of Barrett’s oesophagus and related neoplasia in individuals with a positive family history
|
Peters, Yonne
|
|
|
155 |
C |
p. 116-126
|
artikel
|
| 14 |
Late-onset kidney failure in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study
|
Dieffenbach, Bryan V.
|
|
|
155 |
C |
p. 216-226
|
artikel
|
| 15 |
Late toxicities and recurrences in patients with clinical stage I non-seminomatous germ cell tumours after 1 cycle of adjuvant bleomycin, etoposide and cisplatin versus primary retroperitoneal lymph node dissection – A 13-year follow-up analysis of a phase III trial cohort
|
Hiester, Andreas
|
|
|
155 |
C |
p. 64-72
|
artikel
|
| 16 |
Letter comments on: Mainstreaming informed consent for genomic sequencing: A call for action
|
Dungey, Maurice
|
|
|
155 |
C |
p. 307-309
|
artikel
|
| 17 |
Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network
|
Bianchi, Susanna
|
|
|
155 |
C |
p. 127-135
|
artikel
|
| 18 |
Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysis
|
Wenzel, Mike
|
|
|
155 |
C |
p. 245-255
|
artikel
|
| 19 |
Myalgias upon PD-1 checkpoint blockade: Think of immunotherapy induced hypothyroid myopathy
|
He, Jian
|
|
|
155 |
C |
p. 38-41
|
artikel
|
| 20 |
Nested and adjacent subgroups in cancer clinical trials: When the best interests of companies and patients diverge
|
Kim, Myung S.
|
|
|
155 |
C |
p. 163-167
|
artikel
|
| 21 |
Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial)
|
Lombardi, Giuseppe
|
|
|
155 |
C |
p. 179-190
|
artikel
|
| 22 |
Persistent status of metabolic syndrome and risk of cholangiocarcinoma: A Korean nationwide population-based cohort study
|
Park, Joo-Hyun
|
|
|
155 |
C |
p. 97-105
|
artikel
|
| 23 |
Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials
|
Matos, Ignacio
|
|
|
155 |
C |
p. 168-178
|
artikel
|
| 24 |
Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status
|
Hein, Alexander
|
|
|
155 |
C |
p. 1-12
|
artikel
|
| 25 |
Rare cutaneous toxicity of immune checkpoint inhibitors: A case of durvalumab-induced dermatomyositis
|
Coustal, Cyrille
|
|
|
155 |
C |
p. 25-27
|
artikel
|
| 26 |
Real-world outcomes associated with new cancer medicines approved by the Food and Drug Administration and European Medicines Agency: A retrospective cohort study
|
Boyle, Jemma M.
|
|
|
155 |
C |
p. 136-144
|
artikel
|
| 27 |
Re: Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials
|
Salem, Joe-Elie
|
|
|
155 |
C |
p. 299-302
|
artikel
|
| 28 |
Refusal of anti-coronavirus disease 2019 vaccination in cancer patients: Is there a difference between the sexes?
|
Stoeklé, Henri-Corto
|
|
|
155 |
C |
p. 54-55
|
artikel
|
| 29 |
Re: Post-progression outcomes of NSCLC patients with PD-L1 expression ≥50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study
|
Sütcüoğlu, Osman
|
|
|
155 |
C |
p. 294-295
|
artikel
|
| 30 |
Re: Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy
|
Takada, Kazuki
|
|
|
155 |
C |
p. 313-314
|
artikel
|
| 31 |
Response to letter entitled: Re: Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials
|
Agostinetto, Elisa
|
|
|
155 |
C |
p. 303-306
|
artikel
|
| 32 |
Response to letter entitled: Re: Mainstreaming informed consent for genomic sequencing: A call for action
|
Bunnik, Eline M.
|
|
|
155 |
C |
p. 310-312
|
artikel
|
| 33 |
Response to letter entitled: Re: Predictive ability of a drug-based score in advanced non-small cell lung cancer patients receiving first-line immunotherapy
|
Cortellini, Alessio
|
|
|
155 |
C |
p. 315-316
|
artikel
|
| 34 |
Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour
|
George, Suzanne
|
|
|
155 |
C |
p. 236-244
|
artikel
|
| 35 |
Role of 18F-FDG-PET/CT in the staging of metastatic rhabdomyosarcoma: a report from the European paediatric Soft tissue sarcoma Study Group
|
Mercolini, Federico
|
|
|
155 |
C |
p. 155-162
|
artikel
|
| 36 |
Selenium stimulates the antitumour immunity: Insights to future research
|
Razaghi, Ali
|
|
|
155 |
C |
p. 256-267
|
artikel
|
| 37 |
Squamousness gain defines pancreatic ductal adenocarcinoma hepatic metastases phenotype, and gemcitabine response
|
Fraunhoffer, Nicolas A.
|
|
|
155 |
C |
p. 42-53
|
artikel
|
| 38 |
The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients
|
Zaremba, Anne
|
|
|
155 |
C |
p. 268-280
|
artikel
|
| 39 |
The impact of isolated local recurrence on long-term outcome in early-breast cancer patients after breast-conserving therapy
|
Vrieling, Conny
|
|
|
155 |
C |
p. 28-37
|
artikel
|
| 40 |
Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study
|
Antoniotti, Carlotta
|
|
|
155 |
C |
p. 73-84
|
artikel
|
Tijdschrift beschrijving